

CONTENTS

NOTE TO THE READER.....	1
LIST OF PARTICIPANTS.....	3
PREAMBLE	9
Background	9
Objective and Scope	9
Selection of Topics for Monographs	10
Data for Monographs.....	11
The Working Group.....	11
Working Procedures.....	11
Exposure Data	12
Studies of Cancer in Humans	14
Studies of Cancer in Experimental Animals	17
Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms	20
Summary of Data Reported.....	22
Evaluation	23
References	27
GENERAL REMARKS.....	33
THE MONOGRAPHS	
Oral contraceptives, combined	49
1. Exposure	49
1.1 Historical overview	50
1.2 Patterns of use of combined oral contraceptives	52
1.3 Exposure to other combinations of oestrogen and progestogen	63
2. Studies of cancer in humans	66
2.1 Breast cancer	66
2.2 Endometrial cancer.....	110
2.2.1 Combined oral contraceptives	110
2.2.2 Sequential oral contraceptives	124
2.3 Cervical cancer.....	127
2.3.1 Methodological considerations	127
2.3.2 Descriptive studies.....	130

2.3.3	Cohort studies	131
2.3.4	Case-control studies	136
2.4	Ovarian cancer	156
2.4.1	Descriptive studies	156
2.4.2	Cohort studies	156
2.4.3	Case-control studies	158
2.5	Cancers of the liver and gall-bladder	168
2.5.1	Descriptive studies	168
2.5.2	Cohort studies	169
2.5.3	Case-control studies	170
2.6	Colorectal cancer	180
2.6.1	Cohort studies	180
2.6.2	Case-control studies	182
2.7	Cutaneous malignant melanoma	186
2.7.1	Cohort studies	186
2.7.2	Case-control studies	189
2.8	Retinal melanoma.....	196
2.9	Thyroid cancer	197
2.10	Other cancers	200
3.	Studies of cancer in experimental animals	201
3.1	Oestrogen-progestogen combinations	201
3.1.1	Studies reviewed previously	201
3.1.2	New studies	202
3.2	Oestrogens used in combined oral contraceptives.....	206
3.2.1	Studies reviewed previously	206
3.2.2	New studies	206
3.3	Progestogens used in combined oral contraceptives	213
3.2.1	Studies reviewed previously	213
3.2.2	New studies	216
4.	Other data relevant to an evaluation of carcinogenicity and its mechanisms.....	220
4.1	Absorption, distribution, metabolism and excretion	220
4.1.1	Ethinylestradiol	224
4.1.2	Mestranol	225
4.1.3	Chlormadinone acetate	226
4.1.4	Cyproterone acetate	226
4.1.5	Desogestrel.....	227
4.1.6	Gestodene.....	228
4.1.7	Levonorgestrel	229
4.1.8	Megestrol acetate	231
4.1.9	Norethisterone	232
4.1.10	Lynoestrenol, ethynodiol diacetate and norethynodrel	232

4.1.11	Norgestimate	233
4.1.12	Norgestrel.....	234
4.2	Receptor-mediated effects	234
4.2.1	Combined oral contraceptives	234
4.2.2	Ethinylestradiol	235
4.2.3	Mestranol	237
4.2.4	Chlormadinone acetate	239
4.2.5	Cyproterone acetate	240
4.2.6	Desogestrel.....	243
4.2.7	Ethinodiol diacetate	245
4.2.8	Gestodene.....	245
4.2.9	Levonorgestrel	248
4.2.10	Lynoestrenol.....	250
4.2.11	Megestrol acetate	251
4.2.12	Norethisterone	252
4.2.13	Norethynodrel	255
4.2.14	Norgestimate	256
4.2.15	Norgestrel.....	257
4.3	Genetic and related effects	259
4.3.1	Combined oral contraceptives	259
4.3.2	Ethinylestradiol and some derivatives alone and in combination with progestogens	261
4.3.3	Mestranol alone and in combination with progestogens	261
4.3.4	Cyproterone acetate, metabolites and derivatives	266
4.3.5	Norethisterone alone and in combination with an oestrogen	266
4.3.6	Norethisterone acetate alone and in combination with an oestrogen	272
4.3.7	Chlormadinone acetate	272
4.3.8	Gestodene.....	272
4.3.9	Megestrol acetate	272
4.3.10	Norethynodrel	276
4.3.11	Levonorgestrel	276
4.4	Reproductive and prenatal effects	276
4.4.1	Ethinylestradiol	278
4.4.2	Mestranol	279
4.4.3	Chlormadinone acetate	280
4.4.4	Cyproterone acetate	281
4.4.5	Levonorgestrel	283
4.4.6	Lynoestrenol.....	284
4.4.7	Megestrol acetate	284
4.4.8	Norethisterone	285

4.4.9	Norethynodrel	286
4.4.10	Norgestimate	287
4.4.11	Norgestrel.....	287
5.	Summary of data reported and evaluation	288
5.1	Exposure.....	288
5.2	Human carcinogenicity	289
5.3	Carcinogenicity in experimental animals.....	291
5.4	Other relevant data	293
5.5	Evaluation.....	293
6.	References	294
Hormonal contraceptives, progestogens only		339
1.	Exposure	339
1.1	Historical overview	339
1.2	Injectable progestogens	340
1.2.1	Patterns of use	341
1.2.3	Action.....	343
1.3	Progestogen implants	344
1.3.1	Patterns of use	344
1.3.2	Action.....	344
1.4	Progestogen-only oral contraceptives	344
1.4.1	Patterns of use	345
1.4.2	Action.....	345
1.5	Other sources of exposure to progestogen-only contraceptives	346
2.	Studies of cancer in humans	346
2.1	Breast cancer	346
2.1.1	Results of published studies.....	346
2.1.2	Pooled analysis of individual data.....	350
2.2	Endometrial cancer.....	350
2.2.1	Cohort studies	350
2.2.2	Case-control studies	350
2.3	Cervical cancer.....	352
2.3.1	Methodological considerations	352
2.3.2	Cervical dysplasia and carcinoma <i>in situ</i>	353
2.3.3	Invasive cervical carcinoma.....	354
2.4	Ovarian cancer	360
2.4.1	Cohort studies	360
2.4.2	Case-control studies	360
2.5	Liver cancer	360
2.6	Malignant melanoma	361
3.	Studies of cancer in experimental animals	361
3.1	Medroxyprogesterone acetate	361

3.1.1	Subcutaneous implantation	361
3.1.2	Administration with known carcinogens	366
3.2	Levonorgestrel	369
4.	Other data relevant to an evaluation of carcinogenicity and its mechanisms	370
4.1	Absorption, distribution, metabolism and excretion	370
4.1.1	Medroxyprogesterone acetate	370
4.1.2	Levonorgestrel	371
4.1.3	Norethisterone	372
4.2	Receptor-mediated effects	372
4.2.1	Medroxyprogesterone acetate	372
4.2.2	Levonorgestrel	377
4.3	Genetic and related effects	379
4.3.1	Humans	379
4.3.2	Experimental systems	379
4.4	Reproductive and prenatal effects	379
4.4.1	Medroxyprogesterone acetate	379
4.4.2	Levonorgestrel	382
5.	Summary of data reported and evaluation	383
5.1	Exposure	383
5.2	Human carcinogenicity	383
5.3	Carcinogenicity in experimental animals	384
5.4	Other relevant data	385
5.5	Evaluation	385
6.	References	385
	Post-menopausal oestrogen therapy	399
1.	Exposure	399
1.1	Historical overview	399
1.2	Post-menopausal oestrogen therapy preparations	402
1.2.1	Patterns of use	403
2.	Studies of cancer in humans	407
2.1	Breast cancer	407
2.1.1	Descriptive studies	408
2.1.2	Analytical cohort and case-control studies	408
2.2	Endometrial cancer	430
2.2.1	Descriptive studies	430
2.2.2	Cohort studies	431
2.2.3	Case-control studies	431
2.3	Cervical cancer	437
2.3.1	Methodological considerations	437
2.3.2	Cohort studies	438

2.3.3	Case-control studies	439
2.4	Ovarian cancer	439
2.4.1	Descriptive studies	439
2.4.2	Cohort studies	439
2.4.3	Case-control studies	440
2.5	Liver cancer	445
2.5.1	Cohort studies	445
2.5.2	Case-control studies	446
2.6	Colorectal cancer	446
2.6.1	Descriptive studies	446
2.6.2	Cohort studies	447
2.6.3	Case-control studies	451
2.7	Cutaneous malignant melanoma	457
2.7.1	Descriptive studies	457
2.7.2	Cohort studies	460
2.7.3	Case-control studies	460
2.8	Intraocular malignant melanoma	462
2.9	Thyroid cancer	462
2.9.1	Descriptive studies	462
2.9.2	Case-control studies	462
2.10	Other cancers	465
3.	Studies of cancer in experimental animals	465
3.1	Studies reviewed previously	465
3.2	New studies of oestrogens used in post-menopausal oestrogen therapy	466
3.2.1	Conjugated oestrogens	466
3.2.2	Oestradiol	467
3.2.3	Oestriol	471
3.2.4	Oestrone	473
4.	Other data relevant to an evaluation of carcinogenicity and its mechanisms	474
4.1	Absorption, distribution, metabolism and excretion	474
4.1.1	Humans	474
4.1.2	Experimental systems	480
4.2	Receptor-mediated effects	483
4.2.1	Humans	483
4.2.2	Experimental systems	485
4.3	Genetic and related effects	491
4.3.1	Humans	491
4.3.2	Experimental systems	491
5.	Summary of data reported and evaluation	498
5.1	Exposure	498

5.2	Human carcinogenicity	499
5.3	Carcinogenicity in experimental animals.....	500
5.4	Other relevant data	502
5.5	Evaluation.....	503
6.	References	503
	Postmenopausal oestrogen–progestogen therapy	531
1.	Exposure	531
1.1	Historical overview	531
1.2	Post-menopausal oestrogen–progestogen therapy preparations	532
1.2.1	Patterns of use	533
2.	Studies of cancer in humans	534
2.1	Breast cancer	534
2.1.1	Cohort studies	535
2.1.2	Case–control studies	539
2.1.3	Pooled analysis of individual data.....	541
2.2	Endometrial cancer.....	542
2.2.1	Randomized trial	542
2.2.2	Cohort studies	542
2.2.3	Case–control studies	543
2.3	Ovarian cancer	547
2.3.1	Cohort study.....	547
2.3.2	Case–control study.....	547
2.4	Liver cancer	547
2.5	Colorectal cancer	547
2.5.1	Cohort studies	547
2.5.2	Case–control study.....	549
2.6	Cutaneous malignant melanoma	549
2.6.1	Cohort study.....	549
2.6.2	Case–control study.....	549
3.	Studies of cancer in experimental animals	549
4.	Other data relevant to an evaluation of carcinogenicity and its mechanisms	550
4.1	Absorption, distribution, metabolism and excretion	550
4.1.1	Humans	550
4.1.2	Experimental systems	552
4.2	Receptor-mediated effects	552
4.2.1	Humans	552
4.2.2	Experimental systems	555
4.3	Genetic and related effects.....	556
4.3.1	Humans	556
4.3.2	Experimental systems	556

5. Summary of data reported and evaluation	556
5.1 Exposure.....	556
5.2 Human carcinogenicity	556
5.3 Carcinogenicity in experimental animals.....	557
5.4 Other relevant data	557
5.5 Evaluation.....	558
6. References	558
 SUMMARY OF FINAL EVALUATIONS	 565
 ANNEX 1. Chemical and physical data and information on production and use for oestrogens and progestogens used in oral contraceptives, progestogen-only contraceptives and post-menopausal hormonal therapy	 569
 ANNEX 2. Preparations of oestrogens, progestogens and combinations of oestrogens and progestogens that are or have been used as hormonal contraceptives and for post-menopausal hormonal therapy, with known trade names	 615
 CUMULATIVE INDEX TO THE MONOGRAPHS SERIES	 629

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean the probability that exposure to an agent will lead to cancer in humans.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a monograph does not mean that it is not carcinogenic.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Unit of Carcinogen Identification and Evaluation, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Unit of Carcinogen Identification and Evaluation, so that corrections can be reported in future volumes.